AstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with VaxEquity


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
Latest pharma update

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisation of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.

The strategic, long-term research collaboration aims to optimise and validate VaxEquity’s saRNA platform and apply it to advance novel therapeutic programmes. AstraZeneca will support VaxEquity with research and development funding and should AstraZeneca advance any of the research programmes into its pipeline, VaxEquity could receive development, approval and sales based milestones totalling up to $195 million and royalties in the mid-single digits per programme. AstraZeneca has the option to collaborate with VaxEquity on up to 26 drug targets and will also make an investment in VaxEquity to further the development of the saRNA platform.

VaxEquity was founded by Imperial College London and Morningside in 2020 based on the innovative saRNA technology developed by Professor Robin Shattock and his colleagues at Imperial College London, UK.

saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level. This has the potential to allow saRNAs to be delivered at lower concentrations than conventional mRNA therapeutics, leading to less frequent or lower dosing, lower costs and a much broader range of potential applications. The saRNA platform aims to underpin the next generation of RNA-delivered medicines enabling not only vaccines but also broad range of therapeutic applications.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said “This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox. We believe self-amplifying RNA, once optimised, will allow us to target novel pathways not amenable to traditional drug discovery across our therapy areas of interest.”

Michael Watson, Executive Chairman of VaxEquity, said, “We are delighted to collaborate with AstraZeneca given its strong track record in innovation and welcome them as a new investor. We are also grateful for the ongoing support of our existing investor, Morningside Group. With our self-amplifying RNA platform, we aim to underpin the next generation of RNA-delivered medicines enabling not only vaccines but also broad range of therapeutics applications.”

Professor Alice Gast, President of Imperial College London, said: “I am deeply proud of my colleagues’ work in pioneering self-amplifying RNA technology. This collaboration will help realise our ambition of building a lasting legacy from the great scientific advances Imperial made in this pandemic.”

Tags : #Astrazeneca #sRNA #Vaxequity #BiopharmaceuticalsRD

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

ACT Fibernet Collaborates with Amazon Prime to Offer Prime Lite Benefits to Consumers June 19, 2025
CARE Hospitals Conducts “The Power of 3” Public Awareness Drive at Punjagutta JunctionJune 19, 2025
Legalising key population led health services in Thailand is a gamechangerJune 19, 2025
MGM Healthcare Successfully Performs Rare Endoscopic Skull Base Surgery on a 1-Year-Old with Brain Herniation inside NoseJune 19, 2025
Asian Paints’ Apcolite All Protek redefines the Gold Standard in Interior Paints with Breakthrough ‘Lotus Effect Technology’June 19, 2025
The Soft Touch of Tomorrow: Rural India's Lives Are Being Changed by 3D-Printed LimbsJune 19, 2025
QNET India Celebrates International Yoga Day with Curated Wellness EssentialsJune 18, 2025
illumine Raises $2.5M Seed Funding to Globally Scale Vertical AI Platform for Childcare ManagementJune 18, 2025
Mykare Achieves EBITDA-Positive Status in Elective Surgery Vertical with 80% Revenue GrowthJune 18, 2025
HCG Manavata Cancer Centre Launches Scalp Cooling Therapy To Prevent Chemotherapy-Induced Hair LossJune 18, 2025
Biohacking in India: From Blue Light Glasses to Metabolic TrackingJune 18, 2025
AI-Generated Prescriptions: Will They Ever Be Safe Enough?June 18, 2025
The Role of Panchayats in Public Health: Untapped Potential in Rural GovernanceJune 18, 2025
When Medicines Stop Working: How Communities in India Are Fighting BackJune 18, 2025
Archish Fertility & IVF, India’s First 100% Fully Transparent Fertility Lab, Partners with Amaha Health for Holistic Patient Support & Mental WellbeingJune 17, 2025
Supporting Mental Health in AutismJune 17, 2025
New guidelines for monitoring IBD patients to prevent bowel cancerJune 17, 2025
TTK Prestige Launches Tri-Ply Hexamagic Cookware, Blending Non-Stick Innovation with Triply DurabilityJune 17, 2025
Turning ₹2.35 Crore of Grant into ₹17.9 Crore of Impact: How Villgro-360 ONE’s Capital For Impact is Benefitting Thousands of Marginalised FarmersJune 17, 2025
Online Chikitsa Mitra Rolls Out Mobile App for Specialized, In-Home HealthcareJune 17, 2025